THE THREE-RECEPTOR MAP / SOURCE INDEX

Read the research behind the receptor map.

Single, dual and triple agonism describe receptor targets. The papers cited in this edition investigate the biology, experimental activity and clinical observations behind that map; the number of targets is not a treatment ranking.

This source index connects each original publication to the article that uses it. Keep receptor assays separate from human outcomes, and check whether a comparison was performed directly or assembled from different studies.

4 distinct original-paper links cited across 3 guides in this edition. Each link is counted once, even when several articles cite it.

Showing 4 of 4 original-paper links.

Receptor pharmacology

Original publication

Coskun et al. 2022: LY3437943 triple-receptor agonist discovery and early clinical work (opens the original source in a new tab)

pubmed.ncbi.nlm.nih.gov

Open the original paper

WHY THIS SOURCE IS HERE

What does GLP3 actually mean?
Translate informal GLP3 shorthand into the specific molecules, receptors and evidence that a scientific paper can identify.
Three receptors, several different kinds of evidence
A receptor map that distinguishes structural biology, cell signalling, animal experiments and measured human outcomes.
Single, dual and triple agonists: a comparison without a ranking
Organise metabolic receptor research by target profile, then ask separately what the clinical evidence establishes.

Receptor pharmacology

Original publication

Zhang et al. 2017: Cryo-EM structure of the activated GLP-1 receptor–G-protein complex (opens the original source in a new tab)

pubmed.ncbi.nlm.nih.gov

Open the original paper

WHY THIS SOURCE IS HERE

Three receptors, several different kinds of evidence
A receptor map that distinguishes structural biology, cell signalling, animal experiments and measured human outcomes.

Receptor pharmacology

Original publication

Willard et al. 2020: Imbalanced and biased dual GIP/GLP-1 agonism (opens the original source in a new tab)

pubmed.ncbi.nlm.nih.gov

Open the original paper

WHY THIS SOURCE IS HERE

Three receptors, several different kinds of evidence
A receptor map that distinguishes structural biology, cell signalling, animal experiments and measured human outcomes.
Single, dual and triple agonists: a comparison without a ranking
Organise metabolic receptor research by target profile, then ask separately what the clinical evidence establishes.

Receptor pharmacology

Original publication

Lau et al. 2015: Discovery of the GLP-1 analogue semaglutide (opens the original source in a new tab)

pubmed.ncbi.nlm.nih.gov

Open the original paper

WHY THIS SOURCE IS HERE

Single, dual and triple agonists: a comparison without a ranking
Organise metabolic receptor research by target profile, then ask separately what the clinical evidence establishes.

Coskun et al. 2022: LY3437943 triple-receptor agonist discovery and early clinical work (opens the original source in a new tab)

Zhang et al. 2017: Cryo-EM structure of the activated GLP-1 receptor–G-protein complex (opens the original source in a new tab)

Willard et al. 2020: Imbalanced and biased dual GIP/GLP-1 agonism (opens the original source in a new tab)

Lau et al. 2015: Discovery of the GLP-1 analogue semaglutide (opens the original source in a new tab)

Two destinations.One commitment to context.

Two destinations.
One commitment to context.